Supriya Lifescience, a pharma API manufacturer, made a stellar debut with 55% gains, listing at Rs 425/share against IPO price of Rs 274, amidst positive market sentiments. It has a niche product portfolio of 38 APIs with focus primarily on diverse therapeutic areas. It has consistently been India’s largest exporter of certain niche products with well-balanced presence between regulated and semi/non-regulated markets.
Commenting on the IPO, Sneha Poddar, AVP Retail Research, Motilal Oswal Financial Services said, "We like Supriya for its niche product portfolio, backward integrated business model and robust financials. It is well placed to tap opportunity in the pharma API market given its strong pipeline focused on further diversification."
Disclaimer: IRIS has taken due care and caution in compilation of data for its website. Information has been obtained by IRIS from sources which it considers reliable. However, IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website.
| 